


Catalog Number: BT838

DESCRIPTION					
Source	Mouse myeloma cell line, NS0-derived human 4-1BB/TNFRSF9/CD137 protein				
	Human 4-1BB (Leu24-Gln186) Accession # Q07011	DIEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)	6-His tag	
	N-terminus			C-terminus	

	N-terminus	C-terminus
N-terminal Sequence	Leu24	
Analysis		
Structure / Form	Disulfide linked homodimer, Biotinylated via amines	
Predicted Molecular	45 kDa	
Mass		

SPECIFICATIONS		
SDS-PAGE	52-68 kDa, under reducing conditions.	
Activity	Measured by its binding ability in a functional ELISA.  Biotinylated Recombinant Human 4-1BB/TNFRSF9/CD137 Fc Chimera His-tag (Catalog # BT838) binds Recombinant Human 4-1BB  Ligand/TNFSF9 (Catalog # 2295-4L/CF) with an ED <sub>50</sub> of 4.00-60.0 ng/mL.	
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.	
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.	

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 250 μg/mL in water.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  12 months from date of receipt, -20 to -70 °C as supplied.  1 month, 2 to 8 °C under sterile conditions after reconstitution.  3 months, -20 to -70 °C under sterile conditions after reconstitution.	



Rev. 3/18/2025 Page 1 of 2



## Biotinylated Recombinant Human 4-1BB/TNFRSF9/CD137

Fc Chimera His-tag

Catalog Number: BT838

## BACKGROUND

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteinerich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4<sup>+</sup>, CD8<sup>+</sup>, memory CD8<sup>+</sup>, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction co-stimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8<sup>+</sup> T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and co-stimulates the proliferation and activation of mast cells (9, 10). 4-1BB activation enhances CD8<sup>+</sup> T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients,

## References:

respectively (16, 17).

- 1. Wang, C. et al. (2009) Immunol. Rev. 229:192.
- 2. Schwarz, H. et al. (1993) Gene 134:295.
- 3. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
- 4. Wen, T. et al. (2002) J. Immunol. 168:4897.
- 5. Pulle, G. et al. (2006) J. Immunol. 176:2739.
- 6. Zheng, G. et al. (2004) J. Immunol. 173:2428.
- 7. Kim, D. et al. (2008) J. Immunol. 180:2062.
- 8. Lee, S. et al. (2008) Nat. Immunol. 9:917.
- 9. Choi, B.K. et al. (2009) J. Immunol. 182:4107.
- 10. Nishimoto, H. et al. (2005) Blood 106:4241.
- 11. Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
- 12. Lee, S. et al. (2005) J. Immunol. 174:6803.
- 13. Ma, B.Y. et al. (2005) Blood 106:2002.
- 14. Choi, B.K. et al. (2010) J. Immunol. 185:1404.
- 15. Kim, C. et al. (2011) Diabetes 60:3159.
- 16. Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
- 17. Salih, H.R. et al. (2001) J. Immunol. 167:4059.